NASDAQ:ERYP - Erytech Pharma Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$11.25 +0.41 (+3.78 %)
(As of 07/17/2018 04:00 PM ET)
Previous Close$10.84
Today's Range$10.84 - $11.25
52-Week Range$10.00 - $30.56
Volume235 shs
Average Volume2,823 shs
Market Capitalization$196.93 million
P/E RatioN/A
Dividend YieldN/A
ERYTECH Pharma Société Anonyme, a clinical-stage biopharmaceutical company, develops therapies for rare forms of cancer and orphan diseases in France and internationally. The company is developing a pipeline of product candidates targeting markets with unmet medical need using its proprietary ERYCAPS platform, a technology to encapsulate therapeutic drug substances inside red blood cells. It primarily focuses on the treatment of blood cancers, including acute lymphoblastic leukemia (ALL) and acute myeloid leukemia (AML), by depriving tumors of nutrients necessary for their survival. The company's lead product candidate is Eryaspase, which is in various stages of clinical trails for the treatment of pancreatic cancer, ALL, AML, and solid tumors. It is also developing Erymethionase and Eryminase for the treatment of solid tumors; Eryzyme for the treatment of for rare and specialized conditions; and Erymmune for the treatment of TBD. ERYTECH Pharma Société Anonyme has a research agreement with Fox Chase Cancer Center for the preclinical development of erymethionase for the treatment of homocystinuria; a subcontracting agreement for the production of batches of eryaspase for the company's clinical trials; and a subcontracting framework agreement for the optimization of the manufacturing process of the company's pharma products. ERYTECH Pharma Société Anonyme was founded in 2004 and is based in Lyon, France.

Receive ERYP News and Ratings via Email

Sign-up to receive the latest news and ratings for ERYP and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry N/A


Debt-to-Equity Ratio0.01
Current Ratio16.52
Quick Ratio16.50


Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book Value$11.98 per share
Price / Book0.94


EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net MarginsN/A
Return on EquityN/A
Return on AssetsN/A


Outstanding Shares17,930,000
Market Cap$196.93

The Truth About Cryptocurrencies

Erytech Pharma (NASDAQ:ERYP) Frequently Asked Questions

What is Erytech Pharma's stock symbol?

Erytech Pharma trades on the NASDAQ under the ticker symbol "ERYP."

When is Erytech Pharma's next earnings date?

Erytech Pharma is scheduled to release their next quarterly earnings announcement on Tuesday, August, 21st 2018. View Earnings Estimates for Erytech Pharma.

What price target have analysts set for ERYP?

2 equities research analysts have issued 1 year price objectives for Erytech Pharma's shares. Their predictions range from $43.00 to $43.00. On average, they expect Erytech Pharma's share price to reach $43.00 in the next twelve months. This suggests a possible upside of 282.2% from the stock's current price. View Analyst Ratings for Erytech Pharma.

What is the consensus analysts' recommendation for Erytech Pharma?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Erytech Pharma in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy."

Who are some of Erytech Pharma's key competitors?

Who are Erytech Pharma's key executives?

Erytech Pharma's management team includes the folowing people:
  • Mr. Gil Beyen BVBA, CEO & Chairman (Age 56)
  • Mr. Jérôme Bailly Pharm.D., VP, Director of Pharmaceutical Operations & Deputy GM (Age 39)
  • Mr. Eric Soyer Ph.D., CFO & COO (Age 52)
  • Dr. Alexander Scheer Ph.D., Chief Scientific Officer (Age 56)
  • Dr. Iman El-Hariry M.D., Ph.D., Chief Medical Officer (Age 58)

When did Erytech Pharma IPO?

(ERYP) raised $125 million in an IPO on Friday, November 10th 2017. The company issued 5,300,000 shares at a price of $23.00-$24.00 per share. Jefferies, Cowen and Oddo BHF served as the underwriters for the IPO and JMP Securities was co-manager.

Has Erytech Pharma been receiving favorable news coverage?

News coverage about ERYP stock has trended somewhat positive this week, according to Accern Sentiment Analysis. The research firm scores the sentiment of news coverage by reviewing more than 20 million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Erytech Pharma earned a news impact score of 0.18 on Accern's scale. They also assigned press coverage about the company an impact score of 44.78 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the company's share price in the immediate future.

How do I buy shares of Erytech Pharma?

Shares of ERYP can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Erytech Pharma's stock price today?

One share of ERYP stock can currently be purchased for approximately $11.25.

How big of a company is Erytech Pharma?

Erytech Pharma has a market capitalization of $196.93 million.

MarketBeat Community Rating for Erytech Pharma (NASDAQ ERYP)

Community Ranking:  2.3 out of 5 (star star)
Outperform Votes:  38 (Vote Outperform)
Underperform Votes:  43 (Vote Underperform)
Total Votes:  81
MarketBeat's community ratings are surveys of what our community members think about Erytech Pharma and other stocks. Vote "Outperform" if you believe ERYP will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ERYP will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 7/17/2018 by Staff

Featured Article: Relative Strength Index

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.